Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients
NCT ID: NCT00139945
Last Updated: 2010-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2005-10-31
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle
NCT03878992
The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin
NCT01209416
Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency
NCT00646815
Effects of GH and Lirglutide on AgRP
NCT05681299
Growth Hormone Treatment of Young Growth Hormone-Deficient Adults
NCT00187993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Human acylated ghrelin
5 pmol/kg body weight per min
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Verified hypopituitarism
* Unchanged substitution treatment through 3+ months
* Unchanged additional medical treatment
* Oral and written informed consent
Exclusion Criteria
* Diabetes mellitus
* body mass index \> 30
* Fasting hypoglycemia
* Convulsions
* Allergy to trial products
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Aarhus
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jens Otto L Jorgensen, DrMedSci
Role: PRINCIPAL_INVESTIGATOR
Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lauritzen ES, Jorgensen JOL, Moller N, Nielsen S, Vestergaard ET. Increased lipolysis after infusion of acylated ghrelin: a randomized, double-blinded placebo-controlled trial in hypopituitary patients. Clin Endocrinol (Oxf). 2020 Dec;93(6):672-677. doi: 10.1111/cen.14290. Epub 2020 Aug 3.
Vestergaard ET, Gormsen LC, Jessen N, Lund S, Hansen TK, Moller N, Jorgensen JO. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes. 2008 Dec;57(12):3205-10. doi: 10.2337/db08-0025. Epub 2008 Sep 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004/102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.